Breaking News Instant updates and real-time market news.

AFMD

Affimed N.V.

$2.82

0.01 (0.36%)

, AMRN

Amarin

$14.83

0.53 (3.71%)

08:39
08/15/19
08/15
08:39
08/15/19
08:39

Solebury Trout to hold a conference

9th Annual Hamptons CEO Roundtable Conference will be held in Bridgehampton, NY on August 15.

AFMD

Affimed N.V.

$2.82

0.01 (0.36%)

AMRN

Amarin

$14.83

0.53 (3.71%)

IOVA

Iovance Biotherapeutics

$20.50

-0.86 (-4.03%)

AQXP

Aquinox

$0.00

(0.00%)

ASMB

Assembly Biosciences

$12.35

-0.45 (-3.52%)

BLUS

Bellus Health

$0.00

(0.00%)

BHVN

Biohaven Pharmaceutical

$38.07

-0.755 (-1.94%)

BCLI

BrainStorm

$3.56

-0.21 (-5.57%)

BTX

Ticker changed to LCTX

$0.00

(0.00%)

CASI

Casi Pharmaceuticals

$3.08

(0.00%)

CBMG

Cellular Biomedicine

$12.89

0.64 (5.22%)

GNFT

Genfit

$15.73

-0.73 (-4.44%)

HCM

Hutchison China MediTech

$19.67

-0.45 (-2.24%)

KDMN

Kadmon

$2.54

0.015 (0.59%)

PIRS

Pieris Pharmaceuticals

$5.06

0.01 (0.20%)

PTGX

Protagonist Therapeutics

$9.95

0.25 (2.58%)

SVRA

Savara

$2.31

-0.06 (-2.53%)

SBBP

Strongbridge Biopharma

$2.65

-0.02 (-0.75%)

VTVT

vTv Therapeutics

$1.28

-0.055 (-4.12%)

  • 15

    Aug

  • 04

    Sep

  • 09

    Sep

  • 28

    Sep

AFMD Affimed N.V.
$2.82

0.01 (0.36%)

10/09/18
RHCO
10/09/18
NO CHANGE
Target $5
RHCO
Buy
Affimed N.V. price target lowered to $5 from $7 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Affirmed to $5 after the FDA placed a clinical hold on its T cell engager AFM11 phase 1 trial. The analyst keeps his Buy rating on the shares however, saying he sees no read-through to the company's NK cell engager platform or any impact on the recent NK cell engager Genentech deal. Lawson adds that commentary from the management indicates that the "series adverse events" in the study hold are "likely drug-related and from a CD19-related neurotoxicity" and should not impact the ongoing development of AFM13.
10/09/18
BMOC
10/09/18
NO CHANGE
Target $5
BMOC
Outperform
Affimed N.V.'s clinical trial hold on AFM11 'likely temporary', says BMO Capital
BMO Capital analyst Do Kim kept his Outperform rating and $5 price target on Affirmed N.V., saying the clinical hold placed on its AFM11 phase 1 trial is likely to be "temporary" since the three "serious adverse events" cited were identified as neurotoxicities. While he lowers his probability of success in acute lymphoblastic leukemia to 25% from 30% and keeps his probability in non-Hodgkin lymphoma at a "low" 15%, Kim calls for investors to buy Affirmed shares on weakness since the clinical hold is not likely to become "program ending".
03/28/19
LEER
03/28/19
INITIATION
Target $8
LEER
Outperform
Affimed N.V. initiated with an Outperform at SVB Leerink
SVB Leerink initiated Affimed with an Outperform and $8 price target.
09/11/18
WELS
09/11/18
NO CHANGE
WELS
Amgen's AMG420 risk overstated, says Wells Fargo
Wells Fargo analyst Jim Birchenough believes shares of Bluebird Bio (BLUE) have been under pressure on concerns regarding potential competitive risk to BCMA CAR T therapeutic bb2121 from Amgen's (AMGN) bispecific T cell engager AMG420. The analyst highlights that AMGN420 is a continuous IV infusion and in his opinion not a viable competitor to a single bb2121 cell therapy dose, particularly given long-term durability of response with bb2121. Further, he notes that Amgen's approved first generation CD19 bispecific engager, BLINCYTO, is dosed as a continuous IV for 4 weeks out of every 6 and achieved only $175M in sales in 2017 following 2015 approval. He does not view this dose schedule for first generation bispecific T cell engagers as commercially viable in a more chronic cancer. Additionally, the analyst points out that Affimed (AFMD) also has a preclinical BCMA engager AFM26, established proof-of-concept data for CD30 bispecific AFM13, and upcoming proof-of-concept data for CD19 bispecific AFM11.
AMRN Amarin
$14.83

0.53 (3.71%)

08/14/19
08/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tenet (THC) reinstated with a Neutral at Goldman Sachs. 2. WWE (WWE) initiated with a Buy at Rosenblatt. 3. iHeartMedia (IHRT) initiated with a Buy at BofA/Merrill. 4. Fastly (FSLY) initiated with an Overweight at Piper Jaffray. 5. Amarin (AMRN) initiated with an Outperform at SVB Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/14/19
LEER
08/14/19
INITIATION
Target $26
LEER
Outperform
Amarin initiated with an Outperform at SVB Leerink
SVB Leerink analyst Ami Fadia initiated coverage of Amarin with an Outperform rating and $26 price target. She sees the recent 20% pullback in the stock following news that the FDA will hold an advisory committee meeting to review the supplemental new drug application for Vascepa as offering a good entry point, as she believes that Vascepa's label expansion will be approved by the agency. If approved, she thinks Vascepa sales can grow to over $4B in the U.S. at their peak. Fadia added that the November 14 FDA committee meeting and PDUFA date, which she thinks is likely to be rescheduled for late December, are two catalysts that could drive greater than 20% upside in Amarin shares.
08/13/19
ROTH
08/13/19
NO CHANGE
Target $31
ROTH
Buy
Roth confident Amarin's Vascepa will be 'well-received' by FDA panel
Roth Capital analyst Yasmeen Rahimi noted that the FDA's upcoming Advisory Committee reviewing the sNDA for Amarin's (AMRN) Vascepa will include ten voting and one non-voting committee members, including five endocrinologists, three cardiologists, a biostatistician, a pharmacoepidemiologist, a consumer representative and a non-voting nephrologist. Given that the American Diabetes Association has included Vascepa for CV risk reduction in its recommended treatment guidelines, and the panel has a majority of endocrinologists, she believes that "the committee is primed for a positive reception of Vascepa," Rahimi tells investors. Additionally, the AdCom Chairperson, Dr. Kenneth Burman, previously voted in favor of Novo Nordisk's (NVO) insulin degludec and insulin degludec/aspart when chairing a prior AdCom. Rahimi reads this as a strong sign that he is receptive to new therapies and as a positive for Vascepa's review, she said. The analyst keeps a Buy rating on Amarin shares with a price target of $31.
08/15/19
CANT
08/15/19
NO CHANGE
Target $35
CANT
Overweight
Amarin panel not due to negative found by FDA, says Cantor Fitzgerald
The panel meeting for Amarin's Vascepa is not being held because the FDA found something negative in its review, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Rather, the analyst thinks the FDA may be hosting an AdCom for Vascepa "because the drug will be used in a very large patient population." Further, Amarin has been preparing, and continues to prepare, for the panel, Chen contends. In addition, she cautions against reading the tea leaves on the FDA's assignment and cancellation of AdCom meetings based on some historical examples. The analyst reiterates an Overweight rating on Amarin with a $35 price target. Chen still thinks the peak sales potential of Vascepa is underappreciated at current share levels. The stock closed yesterday up 53c to $14.82.
IOVA Iovance Biotherapeutics
$20.50

-0.86 (-4.03%)

06/03/19
JEFF
06/03/19
NO CHANGE
Target $33
JEFF
Buy
Iovance Biotherapeutics price target raised to $33 from $29 at Jefferies
Jefferies analyst Biren Amin raised his price target for Iovance Biotherapeutics to $33 from $29 saying the company's data "continue to trend in the right direction" for both melanoma and cervical. The analyst believes biologics license applications could be submitted for both indications in 2020 and he keeps a Buy rating on shares of Iovance.
06/28/19
PIPR
06/28/19
NO CHANGE
Target $30
PIPR
Overweight
Iovance Biotherapeutics price target raised to $30 from $20 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro raised his price target for Iovance Biotherapeutics to $30 from $20 after spending two days hosting investor meetings with management. The analyst came away optimistic on a near term favorable regulatory update in cervical cancer. The FDA will, at minimum, accept some subset of the current cohort, which would allow enrollment to complete by the end of 2019 and a filing to occur ahead of the planned late-2020 melanoma submission, Catanzaro tells investors in a research note. As a result, he pushed U.S. cervical revenue into 2021. The analyst keeps an Overweight rating on shares of Iovance.
07/02/19
PIPR
07/02/19
NO CHANGE
Target $30
PIPR
Overweight
Iovance submission on track for second half of 2020, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro says guidance from the FDA, as announced this morning by the company, puts Iovance Biotherapeutics on track for a Biologics License Application in cervical cancer in the second half of 2020. This is a positive outcome and largely in-line with where consensus has moved following the ASCO presentation, Catanzaro tells investors in a research note. He maintains an Overweight rating on Iovance Biotherapeutics with a $30 price target.
07/02/19
HCWC
07/02/19
NO CHANGE
Target $32
HCWC
Buy
H.C. Wainwright reiterates Buy, $32 price target on Iovance
H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics with a $32 price target after the company disclosed updates regarding the regulatory path for LN-145 in cervical cancer. With the possibility for innovaTIL-04 study to be registrational, the company is "reasonably" planning a path for a Biologics License Application submission in the second half of 2020, Pantginis tells investors in a research note. The analyst believes LN-145 "deserves the attention it is receiving." While the primary focus remains on Iovance's initial path to market with lifileucel in melanoma, LN-145 is a "potential rapid follower to commercialization," says Pantginis.
AQXP Aquinox
$0.00

(0.00%)

ASMB Assembly Biosciences
$12.35

-0.45 (-3.52%)

07/16/19
JEFF
07/16/19
NO CHANGE
Target $30
JEFF
Buy
Assembly competitor data further validates class, says Jefferies
The initial hepatitis B virus data by Arbutus Biopharma (ABUS) further validates the class showing "efficacy" consistent with Assembly Bioscience (ASMB) and others, Jefferies analyst Michael Yee tells investors in a research note. The analyst continues to believe the capsid class is active and will play a role in a future hepatitis B virus combination. He believes stocks with exposure "remain cheap" and keeps a Buy rating on Assembly Biosciences with a $30 price target.
11/13/18
JEFF
11/13/18
NO CHANGE
Target $75
JEFF
Buy
Assembly Biosciences shares likely to rally into Phase II data, says Jefferies
Jefferies analyst Michael Yee sees shares of Assembly Biosciences "going back up" into new its Phase II data in the first half of 2019. The company continues to execute on its vision to develop first-in-class and best-in-class core inhibitors, Yee tells investors in a research note. He says that while Street expectations have been lowered on Hepatitis B virus in the past year, interest among key opinion leaders has "only increased as data has been presented and has been notable." The analyst keeps a Buy rating on Assembly Biosciences with a $75 price target.
11/19/18
LEER
11/19/18
INITIATION
Target $45
LEER
Outperform
Assembly Biosciences initiated with an Outperform at Leerink
Leerink analyst Geoffrey Porges started Assembly Biosciences with an Outperform rating and $45 price target. The analyst cited the probability-adjusted value for the cash flows he expects from its lead asset ABI-H0731, which is an oral Core Protein Allosteric Modifier in phase II development for chronic hepatitis B virus. Porges forecasts '731 launching in 2022E and growing to $650M in risk-adjusted revenues.
04/15/19
JMPS
04/15/19
NO CHANGE
Target $116
JMPS
Outperform
Enanta early data on EDP-514 look promising, says JMP Securities
JMP Securities analyst Liisa Bayko said she was impressed with the preclinical data presented by Enanta (ENTA) at the EASL meeting on its HBV core inhibitor candidate EDP-514. When comparing to other core inhibitors in development, EDP-514 "appears at least as potent as the competition" with the exception of Assembly Biosciences' (ASMB) third-generation capsid inhibitor ABI-H3733, said Bayko, who added that EDP-514 has a superior reduction in HBV viral load than ABI-H3733 and a lower EC50 level than Assembly's first- and second-generation inhibitors. Bayko keeps an Outperform rating and $116 price target on Enanta shares.
BLUS Bellus Health
$0.00

(0.00%)

BHVN Biohaven Pharmaceutical
$38.07

-0.755 (-1.94%)

07/01/19
PIPR
07/01/19
NO CHANGE
PIPR
Overweight
Piper says concerns about rimegepant's filing status 'put to bed' by Biohaven
Piper Jaffray analyst Tyler Van Buren noted that Biohaven Pharmaceutical issued a press release about the first patient being enrolled in the Phase 2 trial of rimegepant for the treatment of refractory trigeminal neuralgia, calling "the more interesting disclosure" the company's confirmation of the filing of the rimegepant NDAs for the oral pill and ODT formulations. There had recently been some uncertainty among investors on the status of the rimegepant NDA filings, but he thinks those concerns "can now officially be put to bed." Van Buren, who keeps an Overweight rating Biohaven said he has a high level of confidence in the eventual launch of rimegepant.
07/22/19
ADAM
07/22/19
NO CHANGE
Target $80
ADAM
Buy
Biohaven Pharmaceutical weakness a buying opportunity, says Canaccord
Canaccord analyst Sumant Kulkarni noted the FDA issued a complete response letter on Biohaven Pharmaceuticals' NDA for Nurtec used for ALS. The analyst said the CRL appears to be an unfortunate result of issues with the active pharmaceutical ingredient (API) that Biohaven used in its bioequivalence study in 2017. The API was sourced from Apotex, which has had some FDA issues related to a plant in India. He said although a path forward on Nurtec exists, he views the product as relatively non-core to the company/stock. As a result, he would use the weakness as a buying opportunity. Kulkarni reiterated his Buy rating and lowered his price target to $80 from $84 on Biohaven Pharmaceutical shares.
06/25/19
ADAM
06/25/19
NO CHANGE
Target $84
ADAM
Buy
Biohaven Pharmaceutical weakness a buying opportunity, says Canaccord
Canaccord analyst Sumant Kulkarni hosted meetings with Biohaven Pharmaceuticals management and came away with a heightened confidence in his thesis. The analyst recommended buying the stock on the recent pullback ahead of the crucial migraine prevention data that is expected in Q4. Kulkarni reiterated his Buy rating and $84 price target on Biohaven Pharmaceuticals shares.
07/22/19
CANT
07/22/19
NO CHANGE
Target $87
CANT
Overweight
Biohaven CRL for Nurtec does not affect valuation, says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan believes the Complete Response Letter Biohaven Pharmaceutical received from the FDA for Nurtec does not affect the company's strategy or valuation. The analyst sees the current key value driver as lead candidate rimegepant and does not view the CRL as a sign of regulatory relations mismanagement. He does not expect the Nurtec CRL to read through to other developmental candidates. Duncan reiterates a Buy rating on Biohaven with an $87 price target.
BCLI BrainStorm
$3.56

-0.21 (-5.57%)

10/29/18
HCWC
10/29/18
NO CHANGE
Target $11
HCWC
Buy
BrainStorm's 'distressed valuation' presents opportunity, says H.C. Wainwright
After BrainStorm Cell Therapeutics reported that it spent "just" $3.2M in the third quarter and management reiterated that they continue to anticipate the ALS pivotal trial enrollment is on track to complete by mid-2019, H.C. Wainwright analyst Jason Kolbert said he view's Brainstorm's current valuation as "distressed" given NurOwn's clean safety profile and the fact that it is in a pivotal trial. Applying a 70% probability of success, he maintains a Buy rating and $11 price target on BrainStorm shares.
BTX Ticker changed to LCTX
$0.00

(0.00%)

02/21/19
HCWC
02/21/19
INITIATION
Target $4
HCWC
Buy
BioTime initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started BioTime with a Buy rating and $4 price target. The company has returned its to its roots with a singular focus on cellular therapy for unmet medical needs and has become more deliberate in its strategic decisions for its platform assets, Pantginis tells investors in a research note. He believes believe BioTime is in a "position of strength with regard to its multiple business development options going forward."
07/03/19
BNCH
07/03/19
NO CHANGE
BNCH
Speculative Buy
BioTime sale of OncoCyte shares expands shareholder base, says Benchmark
Benchmark analyst Bruce Jackson noted that OncoCyte's (OCX) majority shareholder, BioTime (BTX), is selling 2.25M of its 14.7M shares in the former. He views the share sale as positive for both, noting that BioTime will gain additional capital and OncoCyte will gain a broader shareholder base. BioTime will still hold about 24% of OncoCyte's stock following the deal's completion and Broadwood Partners will be building on its 15.6% stake by acquiring about 1M of the 2.25M shares being offered, noted Jackson, who keeps a Speculative Buy rating on OncoCyte shares.
06/13/19
RAJA
06/13/19
INITIATION
RAJA
Market Perform
BioTime resumed with a Market Perform at Raymond James
Raymond James analyst Dane Leone resumed BioTime with a Market Perform rating.
02/21/19
02/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. At Home Group (HOME) initiated with a Hold at Loop Capital. 2. Harmonic (HLIT) initiated with a Buy at Stifel. 3. Atkore (ATKR) initiated with a Neutral at Credit Suisse. 4. BioTime (BTX) and Verrica Pharmaceuticals (VRCA) were initiated with a Buy at H.C. Wainwright. 5. Aphria (APHA), KushCo Holdings (KSHB), and HEXO Corp (HEXO) were initiated with a Buy at Seaport Global, while Canopy Growth (CGC), Aurora Cannabis (ACB), and Tilray (TLRY) were initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CASI Casi Pharmaceuticals
$3.08

(0.00%)

CBMG Cellular Biomedicine
$12.89

0.64 (5.22%)

02/06/19
BARD
02/06/19
INITIATION
Target $26
BARD
Cellular Biomedicine initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Cellular Biomedicine (CBMG) with an Outperform rating and a price target of $26. The analyst says the company's manufacturing capacity in cell therapy provide it with an edge in the "underappreciated China market", while its partnership with Novartis' (NVS) Kymriah in China validates its cell therapy manufacturing prowess. Given the multiple cell therapies expected in the next 12 months, Kumar says Cellular Biomedicine "could have a panoply of shots on goal over the coming year."
06/25/19
CANT
06/25/19
INITIATION
Target $27
CANT
Overweight
Cellular Biomedicine initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated Cellular Biomedicine with an Overweight and $27 price target.
06/25/19
06/25/19
INITIATION
Target $27

Overweight
Cantor Fitzgerald bullish on Cellular Biomedicine, initiates with an Overweight
As previously reported, Cantor Fitzgerald analyst Alethia Young started coverage of Cellular Biomedicine with an Overweight and $27 price target. The analyst notes that the company's lead clinical candidate is BCMA targeting CAR-T in multiple myeloma, where Phase I initial data are expected at ASH19 in December. A potential positive early readout should likely position Cellular Biomedicine as a cell-therapy leader in China, she contends. In the mid to long-term, Young thinks the AFP TCR in liver cancer and tumor-infiltrating lymphocytes programs could represent key upside.
GNFT Genfit
$15.73

-0.73 (-4.44%)

05/14/19
HCWC
05/14/19
NO CHANGE
HCWC
H.C. Wainwright affirms Buy on Genfit after positive recommendation from DSMB
H.C. Wainwright analyst Ed Arce affirmed a Buy rating and $72 price target on Genfit after the company announced that the the Data Safety Monitoring Board, or DSMB, of the Phase 3 RESOLVE-IT trial of elafibranor for the treatment of NASH, or nonalcoholic steatohepatitis, had "rendered a positive recommendation for the trial's continuation without any changes. This 36-month safety review is the sixth planned review by the DSMB, and revealed no safety issues with elafibranor." The analyst estimates elafibranor's probability of success at 75% for NASH and 60% for PBC, and utilize a 11.5% discount rate, which he believes is "appropriate for a small-cap development stage biotech."
06/25/19
STFL
06/25/19
INITIATION
Target $126
STFL
Hold
Madrigal Pharmaceuticals initiated with a Hold at Stifel
Stifel analyst Derek Archila initiated Madrigal Pharmaceuticals (MDGL) with a Hold rating and $126 price target, stating that he is positively biased heading into Phase 3 amid emerging evidence that point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. However, he thinks the stock could be volatile around updates from competitors such as Viking Therapeutics (VKTX) and Genfit (GNFT) and sees few catalysts specific to Madrigal to drive shares up in the next 12-18 months, Archila tells investors.
06/25/19
STFL
06/25/19
INITIATION
STFL
Hold
Genfit initiated with a Hold at Stifel
Stifel analyst Derek Archila started Genfit with a Hold rating and EUR21 price target, telling investors that he finds it hard to have conviction about a positive read out for the Phase 3 RESOLVE-IT study of elafibranor in on-alcoholic steatohepatitis based on the drug's current data. He questions the drug's commercial viability if it only demonstrates a marginal benefit on NASH resolution, Archila added in his initiation note.
06/11/19
PIPR
06/11/19
NO CHANGE
Target $8
PIPR
Overweight
Piper cuts CymaBay price target to $8 on 'worst case' results for NASH trial
Piper Jaffray analyst Tyler Van Buren said he did not anticipate that placebo would perform better than seladelpar in CymaBay Therapeutics' (CBAY) Phase 2b study of the drug for the treatment of nonalcoholic steatohepatitis. Calling the NASH trial results a "worst case scenario," Van Buren sees significant risk to the final 52-week data read-out and removed all expectations in NASH from his model. He said the data make seladelpar seem similar to Genfit's (GNFT) elafibranor, though seladelpar has not yet shown improvements in good cholesterol, glucose homeostatis, or insulin resistance. While Van Buren cut his price target on CymaBay shares to $8 from $30 based on the trial results, he keeps an Overweight rating on the shares given the sharp pullback this morning and the support he sees from the company's remaining cash and residual opportunity.
HCM Hutchison China MediTech
$19.67

-0.45 (-2.24%)

07/05/19
MACQ
07/05/19
INITIATION
MACQ
Outperform
Hutchison China MediTech initiated with an Outperform at Macquarie
03/27/19
HSBC
03/27/19
INITIATION
HSBC
Buy
Hutchison China MediTech initiated with a Buy at HSBC
HSBC analyst Steve McGarry earlier today initiated coverage of Hutchison China MediTech with a Buy rating and 5,940 pence price target. The company's late stage oncology pipeline assets are "promising" and "could be transformative," McGarry told investors in a research note. Further, Hutchison has "significant" Pharma and Consumer Health businesses in China that generate sales and profits, adds the analyst.
03/04/19
DBAB
03/04/19
INITIATION
Target $35
DBAB
Buy
Hutchison China MediTech initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Richard Parkes started Hutchison China MediTech with a Buy rating and $35 price target. The analyst believes the shares offer "significant upside potential" as the company leverages its pipeline of cancer-focused drugs in both domestic and global markets.
KDMN Kadmon
$2.54

0.015 (0.59%)

02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/26/19
06/26/19
INITIATION
Target $6

Outperform
Oppenheimer bullish on Kadmon, initiates with an Outperform
As previously reported, Oppenheimer analyst Mark Breidenbach started coverage of Kadmon with an Outperform rating and $6 price target. With a clinical-stage pipeline focused on autoimmune, inflammatory, and fibrotic disease and a pivotal trial on the cusp of completing enrollment, the analyst sees Kadmon as an "overlooked value play" with a favorable risk/reward profile for investors.
06/26/19
06/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Slack Technologies (WORK) initiated with an Outperform at Baird. 2. Virtu Financial (VIRT) initiated with a Buy at Rosenblatt. 3. Kadmon (KDMN) initiated with an Outperform at Oppenheimer. 4. Baxter (BAX) initiated with a Sector Weight at KeyBanc. 5. LiveRamp (RAMP) initiated with a Positive at Susquehanna. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/25/19
OPCO
06/25/19
INITIATION
Target $6
OPCO
Outperform
Kadmon initiated with an Outperform at Oppenheimer
Oppenheimer initiated Kadmon with an Outperform rating and $6 price target.
PIRS Pieris Pharmaceuticals
$5.06

0.01 (0.20%)

05/13/19
BARD
05/13/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform and $5 price target.
07/29/19
WBLR
07/29/19
NO CHANGE
WBLR
Outperform
Updates 'very positive' for upcoming Pieris presentation, says William Blair
Pieris Pharmaceuticals (PIRS) will present Phase Ib safety and efficacy results with PRS-060, an inhaled IL-4R alpha inhibitor, at the upcoming European Respiratory Society International Congress, held September 28 through October 2, William Blair analyst Matt Phipps tells investors in a research note. The poster presentation to be presented on October 1 is titled, "Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," the analyst point out. In addition, AstraZeneca (AZN) plans to initiate a Phase II trial with AZD1402/PRS-060 in the second half of this year, according to its recent earnings presentation, adds Phipps. He views these updates as "very positive" for the upcoming presentation, and believes PRS-060 has "significant potential" in the treatment of asthma patients. Phipps keeps an Outperform rating on Pieris Pharmaceuticals.
05/14/19
BARD
05/14/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform rating and $5 price target, saying he believe's Pieris' anticalin platform has the potential to disrupt biologic therapies in the respiratory and oncology spaces. The analyst called out the company's Phase 1 single ascending dose results for anti-interleukin-4 receptor a Ac PRS060 as potentially validating the drug's utility in asthma and serve as a positive catalyst for shares.
07/30/19
BARD
07/30/19
DOWNGRADE
Target $5
BARD
Neutral
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
Baird analyst Madhu Kumar downgraded Pieris Pharmaceuticals to Neutral from Outperform with an unchanged price target of $5.
PTGX Protagonist Therapeutics
$9.95

0.25 (2.58%)

05/09/19
STFL
05/09/19
UPGRADE
Target $17
STFL
Buy
Stifel upgrades Protagonist Therapeutics to Buy after Janssen opts in
Stifel analyst Adam Walsh last night upgraded Protagonist Therapeutics to Buy from Hold and raised his price target for the shares to $17 from $11. The expansion of the deal between Protagonist and Janssen for PTG-200 and other IL-23 receptor antagonists brings large pharma validation to the former's oral peptide platform, Walsh tells investors in a research note. The analyst now has increased confidence in PTG-200. Janssen's decision to opt-in to further PTG-200 development is supportive of PTG-200's potential in Crohn's and should assuage investor fears around Protagonist's oral peptide technology, says the analyst.
05/08/19
STFL
05/08/19
UPGRADE
Target $17
STFL
Buy
Protagonist Therapeutics upgraded to Buy from Hold at Stifel
Stifel analyst Adam Walsh upgraded Protagonist Therapeutics to Buy from Hold and raised his price target for the shares to $17 from $11.
05/09/19
05/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Atlassian (TEAM) upgraded to Buy from Neutral at Goldman Sachs with Heather Bellini saying consensus billings expectations for Q4 of $361M, or up 30% year-over-year, appear conservative. 2. Match Group (MTCH) upgraded to Neutral from Sell at Goldman Sachs with 3ith analyst Michael Ng stating that the positive stock reaction to Match's in-line Q1 revenue and EBITDA results illustrate the market is more focused on the longer-term investment thesis. 3. Protagonist Therapeutics (PTGX) upgraded to Buy from Hold at Stifel with analyst Adam Walsh saying yhe expansion of the deal between Protagonist and Janssen for PTG-200 and other IL-23 receptor antagonists brings large pharma validation to the former's oral peptide platform. 4. Penn National (PENN) upgraded to Buy from Neutral at BofA/Merrill with analyst Shaun Kelley stating that its core consumer remains stable and he believes catalysts such as the relaunch of MyChoice and sports betting are being underappreciated by investors. 5. Ferrari (RACE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas noting the company's better than expected Q1 results and saying he has higher conviction in the company's strategy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/19
HCWC
07/08/19
INITIATION
Target $23
HCWC
Buy
Protagonist Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao started Protagonist Therapeutics with a Buy rating and $23 price target. While Protagonist's pipeline remains relatively early stage, the Phase 2 data expected later this year for PTG-300 should be an important catalyst for shares since the data may cause investors to assign a much higher valuation to that program, especially as the company should begin work on a second indication, Tsao tells investors in a research note.
SVRA Savara
$2.31

-0.06 (-2.53%)

06/13/19
LTCO
06/13/19
DOWNGRADE
LTCO
Neutral
Savara downgraded to Neutral from Buy at Ladenburg
06/13/19
JMPS
06/13/19
DOWNGRADE
JMPS
Market Perform
Savara downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Liisa Bayko downgraded Savara to Market Perform from Outperform following the failure of the Phase 3 Impala study to meet its primary efficacy endpoint. The Phase 3 study of Molgradex in pulmonary alveolar proteinosis failed to hit the primary endpoint of A-aDO2 gradient reduction due to a higher than expected placebo effect, which is "disappointing setback for the program," Bayko tells investors in a research note. The analyst believes another study will be necessary to support approval.
06/13/19
HCWC
06/13/19
NO CHANGE
Target $6
HCWC
Buy
Savara price target lowered to $6 from $22 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered his price target for Savara to $6 from $22 saying the company reported "highly disappointing" topline results from its pivotal Phase 3 Impala trial. He keeps a Buy rating on the shares.
06/13/19
ADAM
06/13/19
NO CHANGE
Target $15
ADAM
Buy
Savara price target lowered to $15 from $22 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target on Savara to $15 from $22 following its disappointing IMPALA read showing Molgradex can work in PAP despite the IMPALA trial not adequately designed to prove the drug's effectiveness in the orphan designation. The analyst said he will treat IMPALA as essentially a Phase 2 from which the company can build an affective Phase 3 program that could eventually win approval. Steadman maintained his Buy rating on Savara shares.
SBBP Strongbridge Biopharma
$2.65

-0.02 (-0.75%)

12/18/18
LDLW
12/18/18
INITIATION
Target $11
LDLW
Buy
Strongbridge Biopharma initiated with a Buy at Laidlaw
Laidlaw analyst Francois Brisebois started Strongbridge Biopharma with a Buy rating and $11 price target, stating that he views the stock as undervalued at current levels given what he sees as "strong" PHASE 3 Recorlev data and the "impressive commercial potential" of Macrilen.
11/01/18
STFL
11/01/18
NO CHANGE
Target $15
STFL
Buy
Stifel says Strongbridge makes 'right move' to improve Recorlev clinical package
Stifel analyst Annabel Samimy acknowledged that Recorlev development timelines are pushed out by Strongbridge Biopharma (SBBP) expanding LOGICS to strengthen the clinical package. While this results in a three-quarter delay, with top-line now expected in the fourth quarter of 2019 and the launch expectation pushed out to 2021, he believes the company is ultimately making "the right move." He added that the sale of North American rights of Macrelin to Novo Nordisk (NVO) represents a 7.5x return in less than 2 years, but that was overshadowed by Q3 results that showed Keveyis adoption is "proving more challenging." Samimy keeps a Buy rating and $15 price target on Strongbridge Biopharma shares.
VTVT vTv Therapeutics
$1.28

-0.055 (-4.12%)

05/30/19
HCWC
05/30/19
INITIATION
Target $5
HCWC
Buy
vTv Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino started vTv Therapeutics with a Buy rating and $5 price target. The company's focus to further evaluate lead product azeliragon in mild Alzheimer's disease patients with diabetes optimizes the drug's chance for success, Bernardino tells investors in a research note.
05/06/19
NORL
05/06/19
UPGRADE
Target $80
NORL
Outperform
vTv Therapeutics upgraded to Outperform from Market Perform at Northland
Northland analyst Carl Byrnes upgraded vTv Therapeutics to Outperform with a price target of $80, citing the company's progression in its "key clinical programs." In its Azeliragon program, the analyst says the company is set to start screening subjects for its Phase 2 trial starting in June and targeting mild-Alzheimer's disease in patients with type 2 diabetes. Byrnes also says he anticipates part 1 of the Phase 2 Simplici-T1 in June, adding that the company's cash balance and funding agreement with MacAndrews & Forbes allow sufficient funding to operate into 2020.
05/06/19
NORL
05/06/19
UPGRADE
NORL
Outperform
vTv Therapeutics upgraded to Outperform from Market Perform at Northland

TODAY'S FREE FLY STORIES

CMCSA

Comcast

$43.17

0.82 (1.94%)

, AEO

American Eagle

$15.40

0.63 (4.27%)

19:34
08/18/19
08/18
19:34
08/18/19
19:34
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

CMCSA

Comcast

$43.17

0.82 (1.94%)

AEO

American Eagle

$15.40

0.63 (4.27%)

MO

Altria Group

$46.48

1 (2.20%)

CMCSK

Comcast

$0.00

(0.00%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 04

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

19:27
08/18/19
08/18
19:27
08/18/19
19:27
Periodicals
Trump does not want to do business with Huawei, Reuters reports »

President Donald Trump…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYF

X Financial

$2.61

0.04 (1.56%)

19:25
08/18/19
08/18
19:25
08/18/19
19:25
Earnings
X Financial reports Q2 EPS 31c, consensus 22c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

VJET

Voxeljet

$1.64

-0.05 (-2.96%)

18:44
08/18/19
08/18
18:44
08/18/19
18:44
Recommendations
Voxeljet analyst commentary at Piper Jaffray »

Voxeljet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$206.44

4.71 (2.33%)

18:40
08/18/19
08/18
18:40
08/18/19
18:40
Periodicals
Apple CEO warns Trump about China tariffs, Reuters reports »

President Donald Trump…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$206.44

4.71 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

T

AT&T

$34.98

0.64 (1.86%)

, CMCSA

Comcast

$43.17

0.82 (1.94%)

18:05
08/18/19
08/18
18:05
08/18/19
18:05
On The Fly
Box Office Battle: 'Good Boys' wins weekend with $21M debut »

"Box Office Battle" is…

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.72

0.64 (1.16%)

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

LGF.B

Lionsgate

$10.52

0.01 (0.10%)

DIS

Disney

$135.19

1.79 (1.34%)

VIAB

Viacom

$26.02

0.09 (0.35%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Oct

  • 27

    Oct

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

17:59
08/18/19
08/18
17:59
08/18/19
17:59
Periodicals
Softbank plans to lend up to $20B to employees to invest in new fund, WSJ says »

Softbank is planning to…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:50
08/18/19
08/18
16:50
08/18/19
16:50
Periodicals
Trump administration to give Huawei more time to work with U.S. clients,WSJ says »

The Trump administration…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

16:46
08/18/19
08/18
16:46
08/18/19
16:46
Periodicals
J Sainsbury's not talking to internal candidates for CEO succession,Reuters says »

J Sainsbury's is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$219.92

4.27 (1.98%)

16:39
08/18/19
08/18
16:39
08/18/19
16:39
Hot Stocks
Tesla relaunching solar-panel business with no-contract rentals »

Tesla is now offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:14
08/18/19
08/18
16:14
08/18/19
16:14
Periodicals
White House says no recession in sight, Reuters reports »

White House officials…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$89.46

0.91 (1.03%)

16:11
08/18/19
08/18
16:11
08/18/19
16:11
Periodicals
Novartis executive sold shares before data manipulation made public,Reuters says »

An unnamed Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

MO

Altria Group

$46.48

1 (2.20%)

16:08
08/18/19
08/18
16:08
08/18/19
16:08
Periodicals
CDC investigating lung illness linked to e-cigarette use, Reuters reports »

The Centers for Disease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFB

CrossFirst Bancshares

$14.61

(0.00%)

, JFU

9F Inc

$10.09

0.52 (5.43%)

08:48
08/18/19
08/18
08:48
08/18/19
08:48
On The Fly
Opening Day: CrossFirst rises after setting IPO share price lower than expected »

Shares of CrossFirst…

CFB

CrossFirst Bancshares

$14.61

(0.00%)

JFU

9F Inc

$10.09

0.52 (5.43%)

NET

Cloudflare

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

SDC

SmileDirectClub

$0.00

(0.00%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.